These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28083293)

  • 1. Pharmaceutical Pricing: The Use of External Reference Pricing.
    Ruggeri K; Nolte E
    Rand Health Q; 2013; 3(2):6. PubMed ID: 28083293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries.
    Kang SY; DiStefano MJ; Socal MP; Anderson GF
    Health Aff (Millwood); 2019 May; 38(5):804-811. PubMed ID: 31059372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does external reference pricing work in developing countries: evidence from Iran.
    Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
    Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
    [No Abstract]   [Full Text] [Related]  

  • 6. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The End of the International Reference Pricing System?
    Persson U; Jönsson B
    Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in external reference pricing implementation: does it matter for public policy?
    Gill J; Fontrier AM; Kyriopoulos D; Kanavos P
    Eur J Health Econ; 2019 Dec; 20(9):1375-1397. PubMed ID: 31444673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical reference prices. How do they work in practice?
    Dickson M; Redwood H
    Pharmacoeconomics; 1998 Nov; 14(5):471-9. PubMed ID: 10344913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D.
    Schulthess D; Gassull D; Maisel S
    Ther Innov Regul Sci; 2019 Nov; 53(6):746-751. PubMed ID: 31771361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indication-wide drug pricing: Insights from the pharma market.
    Siegmeier F; Büssgen M
    J Pharm Policy Pract; 2022 Aug; 15(1):53. PubMed ID: 36038951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
    Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
    Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: a comparative study among five European recession countries, from a Cyprus perspective.
    Petrou P; Talias MA
    J Pharm Policy Pract; 2016; 9():8. PubMed ID: 26981251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.